Preterm Labor and Birth A Comprehensive Review of Pathophysiology, Clinical Management, and Emerging Strategies
1. Kumar Vinod
2. Osmonova Gulnaz Zhenishbaevna
(1. Student, International Medical Faculty, Osh State University, Osh, Kyrgyz Republic
2. Teacher, International Medical Faculty, Osh State University, Osh, Kyrgyz Republic.)
Abstract
Preterm birth, defined as delivery before 37 completed weeks of gestation, remains one of the most significant challenges in perinatal medicine and a leading cause of neonatal mortality and long-term morbidity worldwide. Approximately 13.4 million infants were born preterm in 2020, representing nearly 10 percent of all live births, with complications of prematurity accounting for roughly one million deaths annually among children under five. This review synthesizes current understanding of the epidemiology, multifactorial pathophysiology, risk factors, diagnostic approaches, and evidence-based management of preterm labor and birth. Spontaneous preterm labor arises from a syndrome involving infection and inflammation, decidual hemorrhage, uterine overdistension, and cervical insufficiency, while indicated preterm births result from maternal or fetal conditions necessitating early delivery. Diagnosis relies on clinical assessment of contractions and cervical change, supplemented by transvaginal cervical length measurement and biomarkers such as fetal fibronectin. Management centers on antenatal corticosteroids for fetal lung maturation, magnesium sulfate for neuroprotection at earlier gestations, short-term tocolysis to permit these interventions or maternal transfer, and group B streptococcus prophylaxis. Prevention strategies include vaginal progesterone for women with short cervix or prior spontaneous preterm birth in selected cases, cervical cerclage when indicated, and emerging blood-based biomarker screening paired with targeted interventions. Despite decades of research, preterm birth rates have remained relatively stable in many high-resource settings, underscoring the need for continued innovation in prediction, prevention, and neonatal care. This article provides an integrated, clinically oriented overview intended for medical students, residents, and practicing clinicians.
Introduction
Few conditions in obstetrics carry the emotional weight and clinical complexity of preterm labor and the subsequent birth of a premature infant. For families, the experience often begins with unexpected contractions or fluid leakage weeks or months before the anticipated due date, followed by rapid transfer to a tertiary center, administration of medications whose names they may never have heard, and the prolonged uncertainty of neonatal intensive care. For clinicians, each case demands simultaneous attention to maternal safety, fetal maturity, the possibility of underlying infection or placental abruption, and the delicate balance between prolonging gestation and avoiding iatrogenic harm.
Preterm birth is conventionally defined as delivery occurring between 20 weeks 0 days and 36 weeks 6 days of gestation. It is further subdivided into extremely preterm (less than 28 weeks), very preterm (28 to less than 32 weeks), moderate preterm (32 to less than 34 weeks), and late preterm (34 to 36 weeks 6 days). These categories matter because survival and the severity of complications rise sharply with advancing gestational age. An infant born at 24 weeks in a high-resource neonatal unit may have a survival chance exceeding 50 to 70 percent with modern intensive care, yet faces substantial risks of chronic lung disease, neurodevelopmental impairment, and sensory deficits. By contrast, a late-preterm infant, while often appearing relatively robust, remains at elevated risk for respiratory distress, hypoglycemia, jaundice, and feeding difficulties compared with term counterparts.
Globally, the burden is staggering. Estimates from 2020 indicate approximately 13.4 million preterm births, corresponding to a worldwide rate of roughly 9.9 percent. The distribution is uneven: the majority occur in Asia and sub-Saharan Africa, where access to antenatal corticosteroids, neonatal resuscitation, and specialized intensive care is limited, resulting in markedly higher mortality. Even in high-income countries, where survival of extremely preterm infants has improved dramatically over the past three decades, preterm birth continues to account for a disproportionate share of neonatal deaths and lifelong disability. In the United States, the preterm birth rate has hovered near 10 percent in recent years, with persistent racial and socioeconomic disparities that reflect deeper inequities in health determinants.
The pathogenesis of preterm labor is no longer viewed as a single pathway but as a syndrome in which multiple etiologic processes converge on a final common pathway of cervical ripening, myometrial activation, and membrane rupture. Infection and inflammation, particularly ascending genital tract infection leading to intra-amniotic inflammation, remain central mechanisms. Decidual hemorrhage, uterine overdistension from multifetal gestation or polyhydramnios, and primary cervical insufficiency each contribute in different patients. Indicated preterm births, arising from preeclampsia, fetal growth restriction, or other maternal-fetal indications, further complicate the epidemiologic picture.
Despite substantial investment in research, rates of preterm birth have proven remarkably resistant to reduction in many settings. Advances in neonatal care have outpaced advances in prevention, shifting the clinical challenge from mere survival toward optimization of long-term neurodevelopmental outcomes. Contemporary practice therefore emphasizes accurate risk stratification, timely administration of interventions that improve neonatal readiness, and thoughtful decisions about the timing and mode of delivery. Emerging tools, including mid-trimester blood-based biomarkers and refined cervical length assessment, offer promise for earlier identification of women who may benefit from targeted preventive measures.
This review aims to provide a coherent, up-to-date synthesis of the anatomy of the problem, the biological mechanisms involved, the practical steps of diagnosis and management, and the evolving landscape of prevention. It is written for clinicians and students who need both a solid foundation and an appreciation of the nuances that arise at the bedside.
Methods
This narrative review was constructed through systematic examination of the peer-reviewed literature, clinical practice guidelines, and authoritative secondary sources published primarily between 2015 and 2026, with inclusion of seminal earlier works that established foundational concepts. Primary databases searched included PubMed/MEDLINE, the Cochrane Library, and Google Scholar, using combinations of terms such as “preterm labor,” “preterm birth,” “spontaneous preterm birth,” “tocolysis,” “antenatal corticosteroids,” “cervical length,” “progesterone,” “fetal fibronectin,” “magnesium sulfate neuroprotection,” and “preterm birth prevention.” Preference was given to systematic reviews, meta-analyses, large cohort studies, randomized controlled trials, and guidelines from the American College of Obstetricians and Gynecologists (ACOG), the World Health Organization (WHO), the Society for Maternal-Fetal Medicine (SMFM), and the Royal College of Obstetricians and Gynaecologists. Epidemiology data were drawn from the most recent global estimates published in The Lancet and WHO reports. Pathophysiologic mechanisms were synthesized from mechanistic reviews and translational studies. Diagnostic and management recommendations reflect current consensus as of early 2026, with explicit notation where evidence remains limited or conflicting. The synthesis prioritizes clinical applicability while acknowledging areas of ongoing controversy and research need. No original patient data were collected; the review is therefore descriptive and interpretive rather than hypothesis-testing.
Results
Epidemiology and Global Burden
Preterm birth affects approximately one in ten pregnancies worldwide. The most recent comprehensive estimates place the number of preterm births in 2020 at 13.4 million, with a global rate of 9.9 percent. Regional variation is pronounced. Rates exceeding 12 percent have been reported in parts of South Asia and certain African nations, while several Northern European countries maintain rates closer to 5 to 6 percent. In the United States, the rate has remained near 10.4 percent in recent years, with late-preterm births constituting the largest share. Racial disparities persist: Black women experience substantially higher rates than White women, a difference that is not fully explained by socioeconomic factors alone and points toward complex interactions of stress, systemic inequities, and biological vulnerability.
Complications of prematurity remain the leading cause of death in children under five years of age, accounting for nearly one million deaths annually. Survival has improved markedly in high-resource settings, particularly for infants born after 28 weeks, yet the absolute number of survivors with long-term morbidity has increased because more extremely preterm infants now live. Neurodevelopmental impairment, chronic lung disease, retinopathy of prematurity, and sensory deficits continue to exact a heavy human and economic toll. The financial burden includes prolonged neonatal intensive care stays, repeated hospitalizations, special education services, and lifelong support for those with significant disability.
Approximately 40 to 45 percent of preterm births follow spontaneous preterm labor with intact membranes, another 25 to 30 percent follow preterm prelabor rupture of membranes, and the remainder are indicated deliveries prompted by maternal or fetal conditions. This distribution has implications for prevention strategies, which have historically focused more successfully on the spontaneous component.
Pathophysiology
Preterm labor is best conceptualized as a syndrome rather than a single disease. Multiple initiating pathways converge on a final common cascade involving activation of the myometrium, cervical remodeling, and, in many cases, membrane rupture. One major pathway is infection and inflammation. Ascending microbial invasion from the lower genital tract can lead to intra-amniotic infection or sterile inflammation mediated by damage-associated molecular patterns. Pro-inflammatory cytokines, particularly interleukin-1, interleukin-6, and tumor necrosis factor-alpha, stimulate prostaglandin production and matrix metalloproteinase activity, resulting in cervical softening, membrane weakening, and uterine contractions. Bacterial vaginosis, urinary tract infection, periodontal disease, and sexually transmitted infections have all been associated with elevated risk, although the precise contribution of each varies.
A second pathway involves decidual hemorrhage and thrombin generation. Placental abruption or occult decidual bleeding activates the coagulation cascade; thrombin in turn stimulates myometrial contractility and matrix degradation. This mechanism helps explain the association between vaginal bleeding in early pregnancy and subsequent preterm birth.
Uterine overdistension constitutes a third pathway. Multifetal gestation, polyhydramnios, or a large singleton fetus stretches myometrial fibers and may trigger the release of inflammatory mediators and prostaglandins. Cervical insufficiency, whether congenital, acquired after surgical procedures, or idiopathic, allows progressive dilation in the absence of strong contractions and often presents with painless cervical change or membrane prolapse.
Endocrine and immune dysregulation further modulate susceptibility. Maternal stress activates the hypothalamic-pituitary-adrenal axis, elevating corticotropin-releasing hormone, which can accelerate placental and fetal endocrine maturation and contribute to labor initiation. Genetic polymorphisms affecting inflammatory responses, collagen metabolism, and progesterone signaling likely interact with environmental exposures to determine individual risk. The net result is that preterm labor represents the endpoint of heterogeneous processes rather than a uniform sequence of events.
Risk Factors
The single strongest predictor of spontaneous preterm birth is a history of prior spontaneous preterm birth. The risk of recurrence rises with the number of previous preterm deliveries and is inversely related to the gestational age of the earliest prior birth. Short cervical length measured by transvaginal ultrasound in the mid-trimester is another powerful marker; lengths below 25 mm confer substantially elevated risk, and lengths below 15 to 20 mm identify a particularly high-risk group. Multifetal gestation multiplies risk through both overdistension and the higher incidence of indicated delivery.
Additional obstetric factors include prior cervical surgery (cone biopsy or large loop excision), uterine anomalies, short interpregnancy interval, and assisted reproductive technology conception. Maternal medical conditions such as hypertensive disorders, diabetes, and autoimmune disease increase the likelihood of indicated preterm birth. Behavioral and social determinants include smoking, substance use, low pre-pregnancy body mass index, inadequate prenatal care, and socioeconomic deprivation. Extremes of maternal age and self-identified Black race remain independent risk factors in multiple large datasets. Infection, whether systemic or local, and periodontal disease also contribute. Importantly, many women who deliver preterm have no identifiable major risk factor, underscoring the limitations of current screening approaches.
Diagnosis
The diagnosis of preterm labor rests on the presence of regular uterine contractions accompanied by progressive cervical change before 37 weeks. ACOG criteria often cite cervical dilation of at least 2 cm in the setting of contractions, although international guidelines sometimes use a 3 cm threshold. In practice, the clinician integrates history, abdominal palpation or tocodynamometry, digital cervical examination, and, when appropriate, sterile speculum examination to assess for membrane rupture or bleeding.
Because many women present with contractions that do not progress to delivery, adjunctive tests improve risk stratification. Transvaginal ultrasound measurement of cervical length is the most widely validated tool. A length greater than 30 mm in a symptomatic woman confers a low likelihood of delivery within seven days, whereas lengths below 20 mm substantially increase that probability. Fetal fibronectin testing of cervicovaginal fluid can further refine prediction; a negative result has a high negative predictive value for delivery within one to two weeks, allowing many women to be safely discharged, while a positive result is less specific.
Evaluation also includes assessment for precipitating or concurrent conditions: urine culture, group B streptococcus screening if not already performed, complete blood count, and, when indicated, testing for sexually transmitted infections. Continuous fetal heart rate monitoring and maternal vital signs help detect fetal compromise or evolving infection. In cases of suspected preterm prelabor rupture of membranes, sterile speculum examination, nitrazine or fern testing, and placental alpha microglobulin-1 assay aid diagnosis, while digital examination is generally avoided to reduce infection risk.
Management
Once preterm labor is diagnosed or strongly suspected, management is guided primarily by gestational age, the presence or absence of membrane rupture, maternal and fetal status, and the proximity of delivery. The overarching goals are to optimize fetal maturity, provide neuroprotection when appropriate, prevent or treat infection, and, when safe, delay delivery long enough to accomplish these aims or to transfer the mother to a facility with appropriate neonatal intensive care capacity.
Antenatal corticosteroids remain the cornerstone of fetal maturation therapy. A single course of betamethasone (12 mg intramuscularly, two doses 24 hours apart) or dexamethasone is recommended for women between 24 weeks 0 days and 33 weeks 6 days who are at risk of preterm delivery within seven days. Administration may be considered as early as 22 or 23 weeks after shared decision-making, and a course may be offered between 34 weeks 0 days and 36 weeks 6 days if the woman has not previously received corticosteroids and delivery is anticipated within seven days. Benefits include reduction in respiratory distress syndrome, intraventricular hemorrhage, necrotizing enterocolitis, and neonatal mortality.
Magnesium sulfate is administered for fetal neuroprotection when delivery is imminent before 32 weeks. Typical regimens involve a loading dose followed by continuous infusion for up to 24 hours or until delivery. Evidence supports a reduction in the risk of cerebral palsy among surviving infants.
Tocolytic therapy is used primarily to achieve short-term prolongation (usually 48 hours) so that corticosteroids and magnesium can be administered and maternal transfer completed. Calcium channel blockers, particularly nifedipine, are commonly first-line agents because of favorable efficacy and side-effect profiles. Indomethacin may be considered before 32 weeks for short courses, with attention to fetal ductus arteriosus constriction and oligohydramnios. Atosiban, an oxytocin receptor antagonist, is widely used outside the United States. Beta-agonists are less favored because of maternal cardiovascular side effects. Prolonged or maintenance tocolysis has not been shown to improve neonatal outcomes and is generally discouraged.
Group B streptococcus prophylaxis with penicillin (or appropriate alternative) is initiated pending culture results or in women with unknown status who are in preterm labor. Antibiotics are not routinely indicated for preterm labor with intact membranes in the absence of infection, but latency antibiotics are recommended in the setting of preterm prelabor rupture of membranes before 34 weeks.
Activity restriction and bed rest have not demonstrated clear benefit and may increase thromboembolic risk and psychological stress; they are therefore not routinely recommended once acute evaluation is complete. Decisions about mode of delivery follow the same principles as at term, with cesarean reserved for standard obstetric indications rather than prematurity alone, except at the extremes of viability where individualized counseling is essential.
Prevention
Primary prevention addresses modifiable risk factors before and during pregnancy: smoking cessation, optimization of pre-pregnancy weight, treatment of infections, adequate interpregnancy intervals, and access to high-quality prenatal care. Secondary prevention focuses on women already identified as high risk.
For women with a singleton pregnancy and a short cervix (less than or equal to 25 mm) in the mid-trimester, vaginal progesterone has been shown to reduce the risk of preterm birth and improve neonatal outcomes. In women with a prior spontaneous preterm birth, current guidance has evolved. Intramuscular 17-alpha-hydroxyprogesterone caproate is no longer routinely recommended for primary prevention in the absence of a short cervix. Vaginal progesterone may still be considered in selected patients with both a history of preterm birth and a short cervix.
Cervical cerclage is indicated for women with a history of second-trimester loss consistent with cervical insufficiency, for those with a short cervix and prior preterm birth in certain protocols, and for emergency or physical-examination-indicated cerclage when membranes are visible or the cervix is dilated. Ultrasound-indicated cerclage in women with short cervix without prior preterm birth remains more controversial and is often reserved for very short lengths.
Emerging strategies include mid-trimester maternal blood biomarker testing, such as the insulin-like growth factor-binding protein 4 to sex hormone-binding globulin ratio. Recent randomized trials have suggested that screen-guided care combining such testing with targeted interventions (vaginal progesterone, low-dose aspirin, and enhanced nursing support) can reduce neonatal morbidity and intensive care utilization even among women previously considered low risk. These approaches are still being refined and are not yet universal standard of care, but they illustrate the direction of future prevention efforts.
Neonatal Outcomes and Long-Term Implications
The spectrum of morbidity associated with preterm birth is broad and gestational-age dependent. Respiratory distress syndrome, bronchopulmonary dysplasia, intraventricular hemorrhage, periventricular leukomalacia, necrotizing enterocolitis, retinopathy of prematurity, sepsis, and patent ductus arteriosus dominate the acute period. Survivors face elevated risks of cerebral palsy, cognitive impairment, behavioral disorders, visual and hearing deficits, and chronic respiratory problems. Late-preterm infants, though less severely affected, still experience higher rates of hospital readmission, feeding difficulties, and subtle developmental delays compared with term infants.
Follow-up programs that provide developmental surveillance, early intervention, and family support are essential. Maternal health after preterm birth also warrants attention; women who experience preterm delivery have higher long-term risks of cardiovascular disease and other chronic conditions, highlighting the need for continuity of care beyond the immediate postpartum period.
Discussion
Preterm labor and birth illustrate both the remarkable progress and the stubborn limitations of modern perinatal medicine. Neonatal intensive care has transformed survival prospects for infants once considered nonviable, yet the incidence of preterm birth itself has proven difficult to reduce. The multifactorial nature of the syndrome explains much of this difficulty: interventions that target a single pathway cannot address the full range of etiologies.
Current management prioritizes fetal readiness over prolonged pregnancy when delivery appears inevitable. The evidence supporting antenatal corticosteroids and magnesium sulfate for neuroprotection is robust and forms the foundation of practice. Tocolysis, while useful for short-term delay, has not improved long-term outcomes when used as maintenance therapy, a finding that has appropriately limited its application. Prevention remains the greatest unmet need. Progesterone and cerclage benefit selected high-risk groups, yet the majority of preterm births occur in women without classic risk factors. Biomarker-guided strategies offer a potential path toward earlier and more precise risk stratification, but widespread implementation will require further validation, cost-effectiveness analysis, and equity considerations so that benefits are not confined to well-resourced settings.
Disparities in preterm birth rates and outcomes demand explicit attention. Social determinants of health, chronic stress, and differential access to care contribute to higher rates among marginalized populations. Research and clinical programs that address these upstream factors are as necessary as pharmacologic and surgical interventions.
Limitations of the present review include the rapidly evolving nature of the evidence base and the predominance of data from high-resource settings. Guidelines and practice patterns continue to change as new trials are published, and clinicians must remain attentive to updates from professional societies. Future progress is likely to come from integrated approaches that combine refined prediction tools, personalized preventive interventions, optimized perinatal care, and sustained investment in neonatal and developmental follow-up.
In the end, every preterm birth represents a story of interrupted development and of the medical and human efforts mobilized in response. The goal of care remains the same as it has always been: to give each infant the best possible start and each family the support they need to navigate an uncertain journey. Continued scientific inquiry, equitable implementation of proven interventions, and compassionate clinical practice together offer the best hope of reducing the burden of prematurity in the years ahead.
References
Ohuma EO, Moller AB, Bradley E, et al. National, regional, and global estimates of preterm birth in 2020, with trends from 2010: a systematic analysis. Lancet. 2023;402(10409):1261-1271.
American College of Obstetricians and Gynecologists. Prediction and Prevention of Spontaneous Preterm Birth. Practice Bulletin No. 234. Obstet Gynecol. 2021;138(2):e65-e90 (reaffirmed 2025).
American College of Obstetricians and Gynecologists. Updated Clinical Guidance for the Use of Progestogen Supplementation for the Prevention of Recurrent Preterm Birth. Practice Advisory. April 2023 (updated 2025).
World Health Organization. WHO recommendations on antenatal corticosteroids and tocolytic therapy for improving preterm birth outcomes. 2022.
Ross MG. Preterm Labor and Birth. Medscape. Updated January 21, 2025.
StatPearls. Preterm Labor. NCBI Bookshelf. Updated February 2025.
Ami O, Maran JC, Gabor P, et al. Three-dimensional magnetic resonance imaging of fetal head molding and brain shape changes during the second stage of labor. PLoS One. 2019;14(5):e0215721. (contextual perinatal imaging literature).
Society for Maternal-Fetal Medicine. Consult Series #71: Management of previable and periviable preterm prelabor rupture of membranes. Am J Obstet Gynecol. 2024.
Cunningham FG, Leveno KJ, et al. Williams Obstetrics. 26th/27th ed. McGraw-Hill.
Goldenberg RL, Culhane JF, Iams JD, Romero R. Epidemiology and causes of preterm birth. Lancet. 2008;371(9606):75-84 (foundational review still widely cited).
Romero R, Dey SK, Fisher SJ. Preterm labor: one syndrome, many causes. Science. 2014;345(6198):760-765.
Conde-Agudelo A, Romero R. Vaginal progesterone to prevent preterm birth in pregnant women with a sonographic short cervix: meta-analysis. Am J Obstet Gynecol. 2018 (and subsequent updates).
PRIME Trial investigators. Biomarker screen-guided care for preterm birth risk. Contemporary reports 2025–2026.
Merck Manual Professional Edition. Preterm Labor. Updated 2024–2025.
Born Too Soon series. Global epidemiology of preterm birth. Reprod Health. 2025.
Bell EF, et al. Mortality, In-Hospital Morbidity, Care Practices, and 2-Year Outcomes for Extremely Preterm Infants. JAMA. 2022;327(3):248-263.